ASND - Ascendis Pharma A/S

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
73.46
-1.26 (-1.69%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close74.72
Open75.00
Bid0.00 x 1200
Ask0.00 x 900
Day's Range72.89 - 75.83
52 Week Range47.80 - 76.99
Volume192,821
Avg. Volume140,783
Market Cap3.088B
Beta (3Y Monthly)1.19
PE Ratio (TTM)N/A
EPS (TTM)-3.87
Earnings DateAug 29, 2017 - Sep 4, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est80.60
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents8 days ago

    Edited Transcript of ASND earnings conference call or presentation 28-Nov-18 9:30pm GMT

    Q3 2018 Ascendis Pharma A/S Earnings Call

  • GlobeNewswire10 days ago

    Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches

    Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant unmet medical needs, today introduced Vision 3x3, the company’s strategic roadmap through 2025 to achieve sustainable growth, at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. “With the clinical validation of our three endocrinology rare disease product candidates, we have built a strong foundation to establish Ascendis as a leading rare disease company,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer.

  • Should You Buy Ascendis Pharma A/S (ASND)?
    Insider Monkeylast month

    Should You Buy Ascendis Pharma A/S (ASND)?

    There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each […]

  • Ascendis Pharma A/S (ASND) Q3 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Ascendis Pharma A/S (ASND) Q3 2018 Earnings Conference Call Transcript

    ASND earnings call for the period ending September 30, 2018.

  • GlobeNewswire2 months ago

    Ascendis Pharma A/S Reports Third Quarter 2018 Financial Results

    - TransCon CNP preliminary phase 1 data support target product profile and further validates TransCon™ technology - - Diversified pipeline with three independent,.

  • GlobeNewswire2 months ago

    Ascendis Pharma A/S Announces Positive Preliminary Phase 1 Data for TransCon CNP

    Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced positive preliminary results from a phase 1 trial of TransCon CNP. Additionally, the mean resting blood pressure and heart rate were unchanged from predose levels at all time points in all cohorts.

  • GlobeNewswire2 months ago

    Ascendis Pharma A/S Announces Third Quarter 2018 Financial Results and Business Update Conference Call on November 28

    Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced that the company will hold a conference call and live webcast on Wednesday, November 28, 2018 at 4:30 p.m. Eastern Time (ET) to review its third quarter 2018 financial results and provide a business update. A live webcast of the conference call will be available on the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives.

  • GlobeNewswire2 months ago

    Ascendis Pharma Announces Formation of VISEN Pharmaceuticals to Develop and Commercialize TransCon™ Endocrinology Rare Disease Therapies in China

    Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced the formation of VISEN Pharmaceuticals (Visen), a joint venture with an investor syndicate led by Vivo Capital, to develop, manufacture and commercialize the company’s endocrinology rare disease therapies in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan.

  • GlobeNewswire2 months ago

    Ascendis Pharma A/S Announces Upcoming Investor Presentations

    Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced that the company will participate in two upcoming investor conferences. A live audio webcast of both events will be available in the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives.

  • ACCESSWIRE4 months ago

    Today's Research Reports on Trending Tickers: Aurora Cannabis and Ascendis Pharma

    NEW YORK, NY / ACCESSWIRE / October 1, 2018 / Major U.S. markets finished flat on Friday. For the third quarter, the S&P 500 Index jumped over 7 percent, its best quarter since 2013, while the Dow Jones ...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of ASND earnings conference call or presentation 29-Aug-18 8:30pm GMT

    Q2 2018 Ascendis Pharma A/S Earnings Call

  • TransCon Tech Is a Major Growth Driver for Ascendis Pharma A/S
    Market Realist4 months ago

    TransCon Tech Is a Major Growth Driver for Ascendis Pharma A/S

    Ascendis Pharma A/S (ASND) is a biopharmaceutical company focused on becoming a leading player in the endocrinology rare disease space by leveraging its TransCon technology to develop multiple prodrug therapies. The 12-month consensus analyst recommendation for Ascendis Pharma A/S on September 23 is a “strong buy.” The 12-month consensus target price for the company is $79, which is 18.80% higher than its last closing price on September 21. Ascendis Pharma A/S closed at $66.50 on September 21, 139.73% higher than its 52-week low of $27.74 and 13.63% lower than its 52-week high of $76.99.

  • Ascendis Pharma (ASND) Q2 2018 Earnings Conference Call Transcript
    Motley Fool5 months ago

    Ascendis Pharma (ASND) Q2 2018 Earnings Conference Call Transcript

    ASND earnings call for the period ending June 30, 2018.

  • ACCESSWIRE5 months ago

    Ascendis Pharma A/S Sponsored ADR to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 29, 2018 / Ascendis Pharma A/S Sponsored ADR (NASDAQ: ASND ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 29, 2018 at 4:30 ...